NASDAQ:VTRS - Viatris Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $18.20
  • Forecasted Upside: 18.95 %
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$15.30
▼ -0.33 (-2.11%)
1 month | 3 months | 12 months
Get New Viatris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTRS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.20
▲ +18.95% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Viatris in the last 3 months. The average price target is $18.20, with a high forecast of $24.00 and a low forecast of $15.00. The average price target represents a 18.95% upside from the last price of $15.30.

Hold

The current consensus among 15 investment analysts is to hold stock in Viatris. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 1 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 1 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageNeutral$16.00N/A
i
6/15/2021CitigroupInitiated CoverageNeutralN/A
i
4/7/2021Royal Bank of CanadaInitiated CoverageOutperform$24.00N/A
i
3/16/2021Morgan StanleyLower Price TargetEqual Weight$18.00 ➝ $16.00N/A
i
3/15/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$20.00 ➝ $15.00N/A
i
3/12/2021Piper SandlerLower Price TargetNeutral$17.00 ➝ $16.00N/A
i
3/10/2021Morgan StanleyLower Price TargetEqual Weight$18.00 ➝ $16.00N/A
i
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$18.00N/A
i
3/8/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$20.00 ➝ $15.00N/A
i
3/2/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$21.00 ➝ $18.00N/A
i
3/1/2021Raymond JamesLower Price TargetOutperform$23.00 ➝ $19.00N/A
i
2/26/2021Wolfe ResearchDowngradeOutperform ➝ Market Perform$17.00N/A
i
2/23/2021Raymond JamesLower Price TargetOutperform$23.00 ➝ $19.00N/A
i
2/23/2021BarclaysLower Price TargetOverweight$26.00 ➝ $20.00N/A
i
2/8/2021SVB LeerinkReiterated RatingMarket PerformN/A
i
Rating by A. Fadia at SVB Leerink LLC
1/25/2021Raymond JamesLower Price TargetOutperform$27.00 ➝ $23.00N/A
i
1/5/2021ArgusInitiated CoverageHoldN/A
i
12/14/2020Sanford C. BernsteinInitiated CoverageMarket Perform$21.00N/A
i
11/24/2020Edward JonesInitiated CoverageSellN/A
i
11/19/2020The Goldman Sachs GroupInitiated CoverageBuy$22.00N/A
i
11/18/2020Edward JonesInitiated CoverageSellN/A
i
11/18/2020BarclaysLower Price TargetOverweight$27.00 ➝ $25.00N/A
i
11/13/2020Bank of AmericaInitiated CoverageBuyN/A
i
(Data available from 6/16/2016 forward)
Viatris logo
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
Read More

Today's Range

Now: $15.30
$15.12
$15.68

50 Day Range

MA: $14.49
$12.97
$16.15

52 Week Range

Now: $15.30
$12.94
$18.86

Volume

6,915,799 shs

Average Volume

10,410,405 shs

Market Capitalization

$18.49 billion

P/E Ratio

3.33

Dividend Yield

2.82%

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Viatris?

The following sell-side analysts have issued reports on Viatris in the last twelve months: Argus, Bank of America Co., Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Edward Jones, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for VTRS.

What is the current price target for Viatris?

10 Wall Street analysts have set twelve-month price targets for Viatris in the last year. Their average twelve-month price target is $18.20, suggesting a possible upside of 19.0%. Royal Bank of Canada has the highest price target set, predicting VTRS will reach $24.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $15.00 for Viatris in the next year.
View the latest price targets for VTRS.

What is the current consensus analyst rating for Viatris?

Viatris currently has 1 sell rating, 10 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VTRS, but not buy more shares or sell existing shares.
View the latest ratings for VTRS.

What other companies compete with Viatris?

How do I contact Viatris' investor relations team?

Viatris' physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is (724) 514-1800 and its investor relations email address is [email protected] The official website for Viatris is www.viatris.com.